Titlebook: Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders; IOIS Guidelines Uwe Pleyer,Jorge L. Alió,Narsing A. Rao Book 2014 The

Flange

書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders影響因子(影響力)




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders影響因子(影響力)學(xué)科排名




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders網(wǎng)絡(luò)公開度




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders被引頻次




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders被引頻次學(xué)科排名




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders年度引用




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders年度引用學(xué)科排名




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders讀者反饋




書目名稱Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders讀者反饋學(xué)科排名

蛤肉

altruism

演講

有節(jié)制

Cystoid Macular Edema,patients is estimated between 20 and 30 % and is a major cause of permanent vision loss [1–3]. About 35 % of uveitis patients with a vision less than 0.1 (6/60) have macular edema, though its prevalence as a cause of poor vision varies with the duration of uveitis. It is reported in 17 % of cases at year 1 and increases to 30 % by year 5 [4].

光亮

978-3-662-50738-4The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer-Verlag GmbH, DE

BARK

Scleroderma

Treatment of Inflammation Secondary to Vitreoretinal Surgery,Vitreoretinal surgery is comprised of a number of techniques, and any of them can cause inflammation for different reasons. This chapter will focus on the treatment of inflammation caused by scleral buckling, pars plana vitrectomy, and combined procedure phacovitrectomy.

Crepitus

lobster

Diagnosis and Management of Scleritis,cond-line immunosuppressive agents. Subconjunctival corticosteroid injection may be an option in non-necrotising noninfectious anterior scleritis, particularly in those who fail to respond to initial systemic therapy. Biologic agents, particularly infliximab and rituximab, may prove useful in refrac